[HTML] nature.comFull View

[HTML][HTML] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu, Q Liu… - Nature …, 2022 - nature.com
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
被引用次数：46 相关文章

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - ideas.repec.org
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li… - Nature …, 2022 - pubmed.ncbi.nlm.nih.gov
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li… - Nature …, 2022 - utsouthwestern.elsevierpure.com
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - search.ebscohost.com
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - europepmc.org
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
[HTML] nih.gov

[HTML][HTML] Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - ncbi.nlm.nih.gov
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily
pretreated patients with advanced triple-negative breast cancer - PMC Back to Top Skip to main …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - econpapers.repec.org
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li, Z Zhu… - Nature …, 2022 - ui.adsabs.harvard.edu
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

J Liu, Y Wang, Z Tian, Y Lin, H Li… - Nature …, 2022 - mdanderson.elsevierpure.com
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …